Exploring the Clinical Need for Levorphanol as a Methadone-Sparing Strategy in Complex Pain Populations

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the clinical scenarios and patient populations that prompted the consideration of Levorphanol as a methadone-sparing option in complex pain management.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the clinical scenarios and patient populations that prompted the consideration of levorphanol as a methadone-sparing option in complex pain management. In this discussion, Kematick provides insight into how evolving challenges in pain management, particularly among patients with refractory or high-risk opioid requirements, have driven clinicians to re-examine older, less commonly utilized opioids such as levorphanol. The conversation focuses on the types of patients who may not achieve adequate analgesia or tolerability with conventional opioid strategies, including methadone, and how individualized therapy becomes essential in these cases.

Kematick highlights clinical settings in which methadone use may be limited by concerns such as drug–drug interactions, variable pharmacokinetics, and safety considerations, prompting clinicians to consider alternative agents with more predictable profiles. He discusses how patients with complex comorbidities, opioid tolerance, or prior inadequate response to standard therapies may represent key populations where levorphanol can serve as a viable option. The interview also examines how levorphanol’s pharmacologic characteristics, including its activity at multiple opioid receptors and NMDA antagonism, may support its use in challenging pain syndromes where traditional opioid approaches fall short.

Additionally, the discussion places emphasis on real-world decision-making in pain management, including how clinicians balance efficacy, safety, and accessibility when selecting opioid therapies. Kematick provides context on how levorphanol may help reduce reliance on methadone in select scenarios while still achieving adequate analgesia in difficult-to-treat patients. The interview ultimately aims to enhance clinician understanding of where levorphanol fits within contemporary opioid stewardship strategies and how it may be integrated into practice as part of a thoughtful, patient-centered approach to managing complex pain conditions.